Lupin Limited Gets Final Go Ahead for its Oxycodone Hydrochloride Tablets

Healthcare, healthcare investing, investing in healthcare, healthcare investments, investing in healthcare mutual funds, investor healthcare, healthcare stocks to invest in, invest in healthcare, healthcare investor, healthcare investment, healthcare stocks today, healthcare investors, healthcare investment bank, healthcare mutual funds, healthcare savings, medicine stocks, healthcare industry companies, medical stocks, healthcare stock, health sector stocks, healthcare stock market, health services stocks, news, investing in pharmaceutical companies, pharmaceutical investment, investing in pharmaceutical stocks, pharmaceutical companies to invest in, best pharmaceutical companies to invest in, pharmaceutical companies stocks, up and coming pharmaceutical companies, drug company stocks, pharmaceutical companies to invest in 2017, pharmaceutical stock, pharmaceutical stocks, pharmaceutical mutual funds, pharmaceutical penny stocks, pharma stocks, pharmaceutical companies, top pharmaceutical stocks, pharmaceutical stocks list, pharmaceutical stocks to watch, best drug company stocks, drug stocks, new pharmaceutical stocks, pharma sector analysis,

Lupin Limited (NSE: LUPIN), a major pharmaceutical company, has acquired the final approval from the United States FDA for its Oxycodone Hydrochloride tablets. These tablets will be used to treat patients suffering from severe pain.

The Mumbai-based company stated in a report that they had received approval from the US FDA to retail its Oxycodone Hydrochloride tablets USP in 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg strengths. Lupin further added that these tablets are a version of Roxicodone tablets developed by Mallinckrodt Inc.

According to Lupin, these tablets are for pain management but only if the pain is severe enough to need an opioid analgesic as alternative treatment methods are not feasible.

Currently, Lupin has 151 product filings awaiting approval from the US FDA and the company’s shares were trading 0.67% higher at Rs 1,185.25 per scrip on BSE on June 14.

Featured Image: twitter

If You Liked This Article Click To Share